Literature DB >> 18408501

Diabetic vitrectomy: the influence of lens status upon surgical outcomes.

Pawan Bhatnagar1, William M Schiff, Gaetano R Barile.   

Abstract

PURPOSE OF REVIEW: Management of the lens in diabetic eyes undergoing vitrectomy has long been a source of controversy. Initially, the lens was removed during diabetic vitrectomy because of intraoperative changes. It was noted, however, that anterior segment neovascular complications were greater in aphakic eyes after diabetic vitrectomy, and subsequently the vitreoretinal surgeon attempted to spare the lens. Lens management in this regard continues to attract discussion. This report reviews recent trends in the management of the native lens in the diabetic eye undergoing vitrectomy. RECENT
FINDINGS: The rate of cataract formation after diabetic vitrectomy is high in eyes left phakic. The rates of anterior segment neovascularization and retinal detachment after diabetic vitrectomy are similar in phakic and nonphakic eyes. The rate of subsequent reoperation after diabetic vitrectomy may be greater in eyes left phakic.
SUMMARY: Although the management of the lens in an eye undergoing diabetic vitrectomy should be individualized, cataract extraction performed either before or in combination with vitrectomy may reduce the rate of subsequent reoperation. The vitreoretinal surgeon may consider rendering an eye nonphakic before or during diabetic vitrectomy to optimize outcomes.

Entities:  

Mesh:

Year:  2008        PMID: 18408501     DOI: 10.1097/ICU.0b013e3282fc25f3

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  3 in total

1.  Pars plana vitrectomy for disturbing primary vitreous floaters: clinical outcome and patient satisfaction.

Authors:  Karlijn F de Nie; N Crama; Maurits A D Tilanus; B Jeroen Klevering; Camiel J F Boon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-12-19       Impact factor: 3.117

2.  Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study.

Authors:  Wai-Ching Lam; David A Albiani; Pradeepa Yoganathan; John Chanchiang Chen; Amin Kherani; David Al Maberley; Alejandro Oliver; Theodore Rabinovitch; Thomas G Sheidow; Eric Tourville; Leah A Wittenberg; Chris Sigouin; Darryl C Baptiste
Journal:  Clin Ophthalmol       Date:  2015-07-10

3.  Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes.

Authors:  Eduardo A Novais; Mauricio Maia; Paulo Augusto de Arruda Mello Filho; João Rafael de Oliveira Dias; José Maurício B B Garcia; Gabriel C de Andrade; Ricardo N Louzada; Marcos Ávila; André Maia; J Fernando Arevalo; Lihteh Wu; Maria Berrocal; Emmerson Badaró; Michel Farah
Journal:  J Ophthalmol       Date:  2016-09-18       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.